What is ADMA's health score?

ADMA BIOLOGICS, INC. (ADMA) has a TradeApes health score of 69 out of 100, rated Healthy. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is ADMA's estimated fair value?

Based on our 5-year discounted cash flow model, ADMA BIOLOGICS, INC.'s estimated fair value is $9.4 per share, representing a 8.3% upside from the current price. This is a model estimate, not a price target or investment recommendation.

Is ADMA undervalued or overvalued?

Our model currently rates ADMA as Fair Value. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Get live scores & alerts on your phone

📱 Get the App

4 free score cards remaining

ADMA BIOLOGICS, INC. (ADMA)

Healthcare Fair Value low healthy

$8.68

Updated: 2026-07-16

TradeApes Score

Financial Strength

80 Strong

Operating Trend

60 Healthy

Relative Value

75 Strong

Capital Allocation

50 Mixed

Risk Management

80 Strong

Est. Fair Value $9.4

DCF Upside +8.3%

Sector Rank #2591 of 12122

Key Findings

+ Historically cheap — EV/EBITDA in bottom 25% of its 5-year range

Unlock Full Report →

− Piotroski F-Score 0–3 — multiple financial weakness signals

Unlock Full Report →

Industry Related Stocks

Acumen Pharmaceuticals, Inc. (ABOS) Abpro Holdings, Inc. (ABPO) Abpro Holdings, Inc. (ABPWW) Arcellx, Inc. (ACLX) Alpha Cognition Inc. (ACOG) Adaptive Biotechnologies Corp (ADPT)

See all Healthcare stocks →

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.